Providing Well-Rounded Care to Patients With Multiple Myeloma: Updates in Proteasome Inhibitor Use, Bone Health, and Digital Monitoring Strategies

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.

Program Description

The management of patients with multiple myeloma (MM) can be challenging due to rapid therapy advances and complexity of new regimens. Proteasome inhibitors (PIs) have become an important cornerstone of treatment. This program will present data from recent clinical trials on the use of PIs in combination therapies. It is especially important for pharmacists to be aware of methods to promote patient adherence to therapy, as regimens are complex and associated with adverse effects. The program will review best practices for the prevention and treatment of myeloma-related bone disease and maintenance of bone health in patients with MM. Faculty will also discuss evolving digital technology and mobile health tools that pharmacists can utilize in the management of patients with MM to improve patient care and communication. This activity will feature a patient perspective interview in which pharmacists will gain insight into a patient’s experience with MM throughout the course of disease from diagnosis to treatment, as well as challenges and management of adverse effects of therapy.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 29, 2022
Expiration date: April 29, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply knowledge of safety and efficacy data of proteasome inhibitors in multiple myeloma (MM) to therapy selection
• Customize a patient-specific supportive care plan to prevent or minimize skeletal-related events as a result of MM
• Explore strategies to improve medication adherence via digital technology

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-195-H01-P. The activity is available for CE credit through April 29, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Megan May, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms